Sofinnova Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sofinnova Investments’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-56,915	Closed	-$2.98M	–	80
2021 Q4	$2.98M	Sell	56,915 -170,504	-75%	-$7.16M	0.17%	59
2021 Q3	$8.48M	Sell	227,419 -85,740	-27%	-$2.98M	0.5%	43
2021 Q2	$12.8M	Sell	313,159 -341,842	-52%	-$12.6M	0.74%	34
2021 Q1	$22.2M	Sell	655,001 -193,161	-23%	-$6.7M	1.34%	21
2020 Q4	$27M	Buy	848,162 +344,607	+68%	+$9.06M	1.61%	16
2020 Q3	$12.9M	Buy	503,555 +261,647	+108%	+$5.97M	0.96%	22
2020 Q2	$6.21M	Buy	241,908 +189,903	+365%	+$3.84M	0.39%	49
2020 Q1	$800K	Buy	+52,005	New	+$1.13M	0.07%	63
2019 Q3	–	Sell	-125,955	Closed	-$1.64M	–	83
2019 Q2	$1.64M	Buy	+125,955	New	+$1.62M	0.15%	62

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sofinnova Investments's ITCI Position: Q1 2022 in Review

Sofinnova Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 56,915 shares — an estimated $2.98M sold.

Sofinnova Investments first reported a position in ITCI in Q2 2019 and held it in 9 quarters. The position peaked at $27M in Q4 2020. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

Sofinnova Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
Sofinnova Investments sold 56,915 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $2.98M.
Sofinnova Investments first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and held it in 9 quarters.
Sofinnova Investments's Intra-Cellular Therapies Inc. position peaked at $27M in Q4 2020.
241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.